Sanofi SAN.PA
Sanofi is a diversified pharmaceutical company that develops and markets medicines in areas such as rare diseases, oncology, immunology, and vaccines, with a business model based on innovation and the sale of prescription products. Sanofi presents a stable financial health (ND/EBITDA 1.27) and an attractive valuation (forward P/E 7.9), but the sharp drop in earnings (-91.2%) and unsustainable payout (127.55%) weigh on its appeal.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Sanofi is a diversified pharmaceutical company that develops and markets medicines in areas such as rare diseases, oncology, immunology, and vaccines, with a business model based on innovation and the sale of prescription products. Sanofi presents a stable financial health (ND/EBITDA 1.27) and an attractive valuation (forward P/E 7.9), but the sharp drop in earnings (-91.2%) and unsustainable payout (127.55%) weigh on its appeal.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.7 |
| Quality / Moat | 6.0 |
| Valuation | 7.4 |
| Growth | 3.8 |
| Dividend | 4.7 |
| Momentum | 2.2 |
| Risk & Context | 7.8 |
OVERALL SCORE: 6.0/10
Context and risks
Regulatory and pricing risk in the pharmaceutical sector, with political pressure on drug costs in Europe and the US. Although there is no specific litigation, Sanofi's exposure to this environment is material.
News considered in the analysis
- Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent — La cartera de nuevos fármacos más allá de Dupixent es una apuesta de crecimiento clave, pero su éxito aún no está garantizado.
- Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines? — Artículo de análisis sin información nueva que afecte a la valoración.
- Amgen price target raised by Jefferies to $410 after positive Sjögren's data — Noticia sobre un competidor directo (Amgen) con datos positivos en una indicación relevante; podría aumentar la competencia, pero no es un hecho material para Sanofi.
- European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading — Ruido de mercado sin información específica sobre la empresa.
- European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance — Noticia sectorial sobre la posición competitiva de Europa, sin impacto directo en los fundamentales de Sanofi.
Verdict: Hold; wait for the new drug pipeline to offset the earnings decline and for the payout to stabilize.
Main risk: The 91.2% drop in earnings and the 127.55% payout indicate a risk of dividend cut if the trend is not reversed.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →